HONG KONG , Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding...
Polyrizon shares have skyrocketed this week on breakthrough preclinical data for its naloxone hydrogen. But PLRZ stock remains a risky proposition heading into 2026.
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...
Polyrizon Ltd. appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs to advance clinical trials.Quiver AI SummaryPolyrizon Ltd., a biotech company focused on innovative intranasal...
Polyrizon partners with Eurofins CDMO for GMP manufacturing to support its upcoming PL-14 clinical trial in 2025.Quiver AI SummaryPolyrizon Ltd., a biotech company in Israel, has announced a manufacturing...
This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.
Polyrizon appoints Asaf Azulay as VP of Regulatory Affairs, enhancing compliance and advancing innovative intranasal hydrogel solutions.Quiver AI SummaryPolyrizon Ltd., a biotech company focused on developing...
Polyrizon partners with Eurofins CDMO for manufacturing PL-14 clinical trial material, enhancing preparation for 2025 trial.Quiver AI SummaryPolyrizon Ltd., a biotech company focused on developing intranasal...